Amgen Says Top-Line Results from Phase 3 Aranesp RED-HF Trial Did Not Meet Primary Endpoint
Amgen (NASDAQ: AMGN) today
announced top-line results of the Phase 3 Aranesp^® (darbepoetin alfa)
RED-HF^® (Reduction of Events With Darbepoetin Alfa in Heart Failure) Trial.
The trial was initiated in 2006, and a total of 2,278 patients with
symptomatic systolic heart failure and anemia (hemoglobin levels ranging from
9.0-12.0 g/dL) were rando
Tags:
Amgen Says Top-Line Results from Phase 3 Aranesp RED-HF Trial Did Not Meet Primary Endpoint,
Amgen Latest News